Featured Research

from universities, journals, and other organizations

New pathway connected to type 2 diabetes

Date:
March 19, 2014
Source:
Children's Hospital of Eastern Ontario Research Institute
Summary:
A cellular pathway that is responsible for keeping blood sugar levels low, has been found, and may prevent the onset of type 2 diabetes. Following a meal, beta cells found in islets of the pancreas secrete insulin that helps to store food energy for future use. The inability of islet beta cells to produce enough insulin leads to diabetes. Unlike other research that has focused on how to replicate beta cells, this study focused on how to make pre-existing beta cells more functional, or better at secreting insulin.

Scientists at the Children's Hospital of Eastern Ontario (CHEO) Research Institute have discovered a cellular pathway that is responsible for keeping blood sugar levels low in obese or pre-diabetic people, and may prevent the onset of Type 2 diabetes. The discovery published this month in a leading journal Nature Cell Biology.

Following a meal, beta cells found in islets of the pancreas secrete insulin that helps to store food energy for future use. The inability of islet beta cells to produce enough insulin leads to diabetes. Unlike other research that has focused on how to replicate beta cells, this study focused on how to make pre-existing beta cells more functional, or better at secreting insulin.

The research team, led by Canada Research Chair Dr. Robert Screaton, senior scientist at the CHEO Research Institute and associate professor at the University of Ottawa, started with a gene "knockout" strategy to remove a protein called SIK2 from all beta cells. They found that mice without SIK2 secrete less insulin during feeding because they fail to turn off a switch protein called p35, which prevents insulin secretion when blood sugar levels are low. The team also found that SIK2 works together with the protein PJA2 to turn off p35.

"We were very excited when we found obese animals had three times the amount of SIK2 in their beta cells, meaning they were working harder to compensate for high blood sugar by turning up SIK2," said Dr. Screaton. "Diabetic mice have lost this ability to turn up SIK2 and compensation is lost. The SIK2-p35-PJA2 pathway provides us with new targets to try and improve beta cell functionality to prevent and treat Type 2 diabetes."


Story Source:

The above story is based on materials provided by Children's Hospital of Eastern Ontario Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jun-Ichi Sakamaki, Accalia Fu, Courtney Reeks, Stephen Baird, Chantal Depatie, Mufida Al Azzabi, Nabeel Bardeesy, Anne-Claude Gingras, Siu-Pok Yee, Robert A. Screaton. Role of the SIK2–p35–PJA2 complex in pancreatic β-cell functional compensation. Nature Cell Biology, 2014; 16 (3): 234 DOI: 10.1038/ncb2919

Cite This Page:

Children's Hospital of Eastern Ontario Research Institute. "New pathway connected to type 2 diabetes." ScienceDaily. ScienceDaily, 19 March 2014. <www.sciencedaily.com/releases/2014/03/140319094223.htm>.
Children's Hospital of Eastern Ontario Research Institute. (2014, March 19). New pathway connected to type 2 diabetes. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/03/140319094223.htm
Children's Hospital of Eastern Ontario Research Institute. "New pathway connected to type 2 diabetes." ScienceDaily. www.sciencedaily.com/releases/2014/03/140319094223.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins